Sign Out
Cardiomyopathy, Infusion Reactions, Embryo-fetal Toxicity, and Pulmonary Toxicity: Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Trastuzumab for cardiomyopathy.
Infusion Reactions, Pulmonary Toxicity: Discontinue Trastuzumab (Ogivri) for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
Embryo-Fetal Toxicity: Exposure to Trastuzumab (Ogivri) during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception.
Continue with Google